Global Peptide-based Injectable Drugs Market Research Report 2025

Publication ID:

PB505255018

Publication Date:

May 29, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Peptide-based Injectable Drugs was valued at US$ 35190 million in the year 2024 and is projected to reach a revised size of US$ 47050 million by 2031, growing at a CAGR of 4.3% during the forecast period.
Peptide-based injectable drugs refer to medications that contain peptides as their active ingredients and are administered via injection. Peptides are short chains of amino acids, which are the building blocks of proteins. They play crucial roles in various biological processes and can be used therapeutically to target specific cellular pathways or receptors.
Injectable peptide drugs offer several advantages over other administration routes, such as oral or topical delivery. When injected, peptides can bypass the gastrointestinal tract, avoiding issues such as degradation by stomach acid or poor absorption. Additionally, injections can provide a more rapid and direct delivery of the drug into the bloodstream, allowing for faster onset of action.
This report aims to provide a comprehensive presentation of the global market for Peptide-based Injectable Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide-based Injectable Drugs.
The Peptide-based Injectable Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Peptide-based Injectable Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peptide-based Injectable Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi
Teva
Novo Nordisk
Takeda
Eli Lilly
AstraZeneca
Novartis
AbbVie
Ipsen
Ferring
Merck
The Medicines
Roche
J & J
Segment by Type
Brand
Generic Drug
Segment by Application
Cancer
Metabolic Disorders
Central Nervous System
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide-based Injectable Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide-based Injectable Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Brand
1.2.3 Generic Drug
1.3 Market by Application
1.3.1 Global Peptide-based Injectable Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Cancer
1.3.3 Metabolic Disorders
1.3.4 Central Nervous System
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide-based Injectable Drugs Market Perspective (2020-2031)
2.2 Global Peptide-based Injectable Drugs Growth Trends by Region
2.2.1 Global Peptide-based Injectable Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Peptide-based Injectable Drugs Historic Market Size by Region (2020-2025)
2.2.3 Peptide-based Injectable Drugs Forecasted Market Size by Region (2026-2031)
2.3 Peptide-based Injectable Drugs Market Dynamics
2.3.1 Peptide-based Injectable Drugs Industry Trends
2.3.2 Peptide-based Injectable Drugs Market Drivers
2.3.3 Peptide-based Injectable Drugs Market Challenges
2.3.4 Peptide-based Injectable Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peptide-based Injectable Drugs Players by Revenue
3.1.1 Global Top Peptide-based Injectable Drugs Players by Revenue (2020-2025)
3.1.2 Global Peptide-based Injectable Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Peptide-based Injectable Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Peptide-based Injectable Drugs Revenue
3.4 Global Peptide-based Injectable Drugs Market Concentration Ratio
3.4.1 Global Peptide-based Injectable Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide-based Injectable Drugs Revenue in 2024
3.5 Global Key Players of Peptide-based Injectable Drugs Head office and Area Served
3.6 Global Key Players of Peptide-based Injectable Drugs, Product and Application
3.7 Global Key Players of Peptide-based Injectable Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Peptide-based Injectable Drugs Breakdown Data by Type
4.1 Global Peptide-based Injectable Drugs Historic Market Size by Type (2020-2025)
4.2 Global Peptide-based Injectable Drugs Forecasted Market Size by Type (2026-2031)
5 Peptide-based Injectable Drugs Breakdown Data by Application
5.1 Global Peptide-based Injectable Drugs Historic Market Size by Application (2020-2025)
5.2 Global Peptide-based Injectable Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Peptide-based Injectable Drugs Market Size (2020-2031)
6.2 North America Peptide-based Injectable Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Peptide-based Injectable Drugs Market Size by Country (2020-2025)
6.4 North America Peptide-based Injectable Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peptide-based Injectable Drugs Market Size (2020-2031)
7.2 Europe Peptide-based Injectable Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Peptide-based Injectable Drugs Market Size by Country (2020-2025)
7.4 Europe Peptide-based Injectable Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peptide-based Injectable Drugs Market Size (2020-2031)
8.2 Asia-Pacific Peptide-based Injectable Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Peptide-based Injectable Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Peptide-based Injectable Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peptide-based Injectable Drugs Market Size (2020-2031)
9.2 Latin America Peptide-based Injectable Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Peptide-based Injectable Drugs Market Size by Country (2020-2025)
9.4 Latin America Peptide-based Injectable Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peptide-based Injectable Drugs Market Size (2020-2031)
10.2 Middle East & Africa Peptide-based Injectable Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Peptide-based Injectable Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Peptide-based Injectable Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Peptide-based Injectable Drugs Introduction
11.1.4 Sanofi Revenue in Peptide-based Injectable Drugs Business (2020-2025)
11.1.5 Sanofi Recent Development
11.2 Teva
11.2.1 Teva Company Details
11.2.2 Teva Business Overview
11.2.3 Teva Peptide-based Injectable Drugs Introduction
11.2.4 Teva Revenue in Peptide-based Injectable Drugs Business (2020-2025)
11.2.5 Teva Recent Development
11.3 Novo Nordisk
11.3.1 Novo Nordisk Company Details
11.3.2 Novo Nordisk Business Overview
11.3.3 Novo Nordisk Peptide-based Injectable Drugs Introduction
11.3.4 Novo Nordisk Revenue in Peptide-based Injectable Drugs Business (2020-2025)
11.3.5 Novo Nordisk Recent Development
11.4 Takeda
11.4.1 Takeda Company Details
11.4.2 Takeda Business Overview
11.4.3 Takeda Peptide-based Injectable Drugs Introduction
11.4.4 Takeda Revenue in Peptide-based Injectable Drugs Business (2020-2025)
11.4.5 Takeda Recent Development
11.5 Eli Lilly
11.5.1 Eli Lilly Company Details
11.5.2 Eli Lilly Business Overview
11.5.3 Eli Lilly Peptide-based Injectable Drugs Introduction
11.5.4 Eli Lilly Revenue in Peptide-based Injectable Drugs Business (2020-2025)
11.5.5 Eli Lilly Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Details
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Peptide-based Injectable Drugs Introduction
11.6.4 AstraZeneca Revenue in Peptide-based Injectable Drugs Business (2020-2025)
11.6.5 AstraZeneca Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Peptide-based Injectable Drugs Introduction
11.7.4 Novartis Revenue in Peptide-based Injectable Drugs Business (2020-2025)
11.7.5 Novartis Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Details
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Peptide-based Injectable Drugs Introduction
11.8.4 AbbVie Revenue in Peptide-based Injectable Drugs Business (2020-2025)
11.8.5 AbbVie Recent Development
11.9 Ipsen
11.9.1 Ipsen Company Details
11.9.2 Ipsen Business Overview
11.9.3 Ipsen Peptide-based Injectable Drugs Introduction
11.9.4 Ipsen Revenue in Peptide-based Injectable Drugs Business (2020-2025)
11.9.5 Ipsen Recent Development
11.10 Ferring
11.10.1 Ferring Company Details
11.10.2 Ferring Business Overview
11.10.3 Ferring Peptide-based Injectable Drugs Introduction
11.10.4 Ferring Revenue in Peptide-based Injectable Drugs Business (2020-2025)
11.10.5 Ferring Recent Development
11.11 Merck
11.11.1 Merck Company Details
11.11.2 Merck Business Overview
11.11.3 Merck Peptide-based Injectable Drugs Introduction
11.11.4 Merck Revenue in Peptide-based Injectable Drugs Business (2020-2025)
11.11.5 Merck Recent Development
11.12 The Medicines
11.12.1 The Medicines Company Details
11.12.2 The Medicines Business Overview
11.12.3 The Medicines Peptide-based Injectable Drugs Introduction
11.12.4 The Medicines Revenue in Peptide-based Injectable Drugs Business (2020-2025)
11.12.5 The Medicines Recent Development
11.13 Roche
11.13.1 Roche Company Details
11.13.2 Roche Business Overview
11.13.3 Roche Peptide-based Injectable Drugs Introduction
11.13.4 Roche Revenue in Peptide-based Injectable Drugs Business (2020-2025)
11.13.5 Roche Recent Development
11.14 J & J
11.14.1 J & J Company Details
11.14.2 J & J Business Overview
11.14.3 J & J Peptide-based Injectable Drugs Introduction
11.14.4 J & J Revenue in Peptide-based Injectable Drugs Business (2020-2025)
11.14.5 J & J Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Sanofi
Teva
Novo Nordisk
Takeda
Eli Lilly
AstraZeneca
Novartis
AbbVie
Ipsen
Ferring
Merck
The Medicines
Roche
J & J

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂